Spyre Therapeutics Stock Forecast

Stock Price Forecast

According to 17 analysts polled by S&P Global, Spyre Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $122.14. The average 1-year stock price forecast is 17.86% higher than the current stock price, while the lowest is $97 (-6.40%) and the highest is $135 (+30.27%).

Price Target: $122.14 (+17.86%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$97	$122.14	$123.5	$135
Change	-6.40%	+17.86%	+19.17%	+30.27%

Analyst Ratings

The average analyst rating for Spyre Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	16	17	17	17	16	16
Buy	0	0	0	0	0	0
Hold	0	0	0	0	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	16	17	17	17	17	17

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Alex Thompson CFA Stifel Nicolaus	Stifel Nicolaus	Buy Maintains $123	Buy	Maintains	$123	+18.69%	Aug 13, 2026
Debanjana Chatterjee JonesTrading	JonesTrading	Buy Maintains $104 → $140	Buy	Maintains	$104 → $140	+35.10%	Aug 12, 2026
David Nierengarten Wedbush	Wedbush	Buy Maintains $130	Buy	Maintains	$130	+25.45%	Aug 11, 2026
Sam Slutsky LifeSci Capital	LifeSci Capital	Buy Maintains $128 → $129	Buy	Maintains	$128 → $129	+24.48%	Aug 11, 2026
Julian Harrison BTIG	BTIG	Buy Reiterates $112 → $132	Buy	Reiterates	$112 → $132	+27.38%	Aug 11, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-2.83

from -1.98

EPS Next Year

-3.44

from -2.83

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	18.74M	2.33M	886.00K	-	-	-
Operating Income	-65.65M	-84.78M	-117.61M	-208.57M	-219.56M	-264.00M
Net Income	-65.80M	-83.82M	-338.79M	-208.02M	-155.20M	-255.83M
EPS	-	-	-	-	-1.98	-2.83
Free Cash Flow	-30.62M	-50.01M	-9.61M	-66.57M	-103.85M	-212.00M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

Chart

EPS	2026	2027	2028
High	-2.19
Avg	-2.83
Low	-4.81

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-